Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Jazz Pharmaceuticals

Explore full profile

Identifying, developing and commercializing meaningful products that address unmet medical needs

Dublin, IrelandFounded 2003Biotech & Life Sciences
Valuation $18B Market cap · Aug/2026
Revenue $4.51B Latest reported FY
EBITDA $2.14B Latest reported FY

At a glance

Founded
2003
Headquarters
Dublin, Ireland
Listing
IPO 2007
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning Jazz Pharmaceuticals.

See all news

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later7 investors entered at this stage

  • Beecken Petty O'Keefe & Company
  • Adams Street Partners
  • Lehman Brothers
  • EGS Healthcare Capital Partners
  • Golden Gate Capital
  • Prospect Venture Partners
  • Thoma Cressey Equity Partners
Employees mapped 3,650 incl. 19 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
33 countries with
team presence
🇺🇸 United States54.1%
🇬🇧 United Kingdom21.1%
🇮🇪 Ireland7.2%
🇮🇹 Italy4.2%
🇨🇦 Canada2.8%
Top 5 of 33 shown
Web traffic by country
92K monthly visits
across markets
🇺🇸 United States60.7%
🇬🇧 United Kingdom11.7%
🇨🇦 Canada4.6%
🇦🇺 Australia2.6%
🇮🇪 Ireland2.4%
Top 5 markets shown

Patents

Estimated portfolio value
$463M

232 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Jazz Pharmaceuticals was the backer or acquirer, 2012–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

12 deals across Jazz Pharmaceuticals's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Jazz Pharmaceuticals deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Jazz Pharmaceuticals's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        12 of 12 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Jazz Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Jazz Pharmaceuticals on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.